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Abstract
Background: Barrett’s esophagus is a premalignant condition whereby the normal stratified squamous esophageal
epithelium undergoes a transdifferentiation program resulting in a simple columnar epithelium reminiscent of the small
intestine. These changes are typically associated with the stratified squamous epithelium chronically exposed to acid and
bile salts as a result of gastroesophageal reflux disease (GERD). Despite this well-defined epidemiologic association between
acid reflux and Barrett’s esophagus, the genetic changes that induce this transdifferentiation process in esophageal
keratinocytes have remained undefined.
Methodology/Principal Findings: To begin to identify the genetic changes responsible for transdifferentiaiton in Barrett’s
esophagus, we performed a microarray analysis of normal esophageal, Barrett’s esophagus and small intestinal biopsy
specimens to identify candidate signaling pathways and transcription factors that may be involved. Through this screen we
identified the Cdx1 homeodomain transcription factor and the c-myc pathway as possible candidates. Cdx1 and c-myc were
then tested for their ability to induce transdifferentiation in immortalized human esophageal keratinocytes using
organotypic culturing methods. Analyses of these cultures reveal that c-myc and cdx1 cooperate to induce mucin
production and changes in keratin expression that are observed in the epithelium of Barrett’s esophagus.
Conclusions/Significance: These data demonstrate the ability of Cdx1 and c-myc to initiate the earliest stages of
transdifferentiation of esophageal keratinocytes toward a cell fate characteristic of Barrett’s esophagus.
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Introduction
The normal esophageal squamous epithelium comprises an
exquisitely regulated equilibrium between the proliferative basal
cell compartment, the differentiating suprabasal cell compartment
and the terminally differentiated superficial layer. Migrating cells
eventually slough into the lumen due to senescence and apoptosis.
A variety of signals trigger epithelial renewal during normal
homeostasis and tissue regeneration, the latter due to infections,
radiation, and acid/bile exposure. However, prolonged acid
exposure, acting alone or in concert with other caustic agents,
are believed to cause transdifferentiation that involves the
replacement of the normal esophageal epithelium with one that
resembles the small intestinal epithelium, designated as incomplete
intestinal metaplasia since two of four cell types are evident [1].
These are the columnar enterocytes and the secretory goblet cells,
and provide the hallmark features of Barrett’s esophagus, in turn a
precursor to esophageal adenocarcinoma [2]. While a wealth of
epidemiological data exist surrounding Barrett’s esophagus and
adenocarcinoma [3,4], the ability to define causative underlying
molecular mechanisms, and in particular, the ability to model this
condition have remained elusive.
Many genes increase in expression in Barrett’s esophagus when
compared to the normal epithelium of the esophagus [5–10].
Among these genes are the Cdx transcription factors, Cdx1 and
Cdx2. These caudal-type homeobox transcription factors deter-
mine cell fate in the developing intestine. Cdx1 and Cdx2 induce
the primitive epithelium of the intestine and colon toward a
glandular cell fate ultimately resulting in the mature intestinal and
colonic epithelia of the adult [11]. It is thought that the cell fates of
the alimentary canal are determined by the abundance of these
transcription factors. Indeed, when Cdx2 is overexpressed in the
glandular epithelium of the stomach in mice, intestinal metaplasia
occurs [12–14]. These data suggest that Cdx transcription factors
can shift the cell fates of glandular cells and suggests they may also
be involved in the progression of Barrett’s esophagus. However,
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are less clear. Cdx1 gene expression and activity are regulated in
colon cancer progression [15–17]. Cdx1 expression decreases in
adenomatous polyps and correlates with increased dysplasia in
Barrett’s esophagus. The most recognized mechanism for
decreased expression is due to hypermethylation of the Cdx1
promoter of Cdx1 [18,19]. Interestingly, a similar type of Cdx1
regulation has been observed in Barrett’s esophagus and intestinal-
type gastric adenocarcinoma [20]. These data suggest that Cdx1
may play a role in the intestinal metaplasia that results in Barrett’s
esophagus, but may also subsequently serve as a tumor suppressor
gene following transdifferentiation.
C-myc is a classic proto-oncogene that is a transcription factor
that binds E-boxes as a heterodimer with Max in about 15% of all
genes, and recruits co-activators to regulate gene transcription
[21–24]. C-myc is regulated in part through mitogenic stimuli, and
is activated constitutively in cancer cells through gene amplifica-
tion, chromosomal translocation, point mutation and mitogenic
stimulation [25]. The consequences of c-myc transcriptional
regulation are protean on cellular behavior, ranging from
modulating proliferation, cellular metabolism, apoptosis and
differentiation in many diverse cell types [25]. The transcriptional
activity of c-myc is dependent upon its ability to dimerize with
Max. Mxd1 (Mad1) and Mxi1 (Mad2) are negative regulators of c-
myc transcriptional activity and function by binding to Max and
sequestering it from c-myc. Regulation of c-myc bound promoter
activity is complex and involves several different types of co-
activators. They include histone actetlytransferases such as p300/
CBP and GCN5; ATPases including TIP48 and TIP49; and the
Mediator complex as well as the several others through c-myc’s
interaction with TRRAP [26–30].
Through a microarray comparison of the normal stratified
squamous epithelium of the esophagus, Barrett’s esophagus and
the normal small intestine, and accompanying validation, the
molecular signature of Barrett’s esophagus highlights the impor-
tance of both Cdx1 and c-myc. We find that both transcription
factors cooperate to induce the earliest stages in this transdiffer-
entiation program towards Barrett’s esophagus as revealed by
organotypic culture (3-dimensional or 3D culture) that mimics the
tissue microenvironment.
Results
To begin to identify genes involved in the transdifferentiation
process we analyzed Barrett’s esophagus (with no dysplasia),
normal esophagus and small intestine biopsy samples by
Affymetrix microarray. PCA analysis of the array data revealed
reproducibility of all samples (Figure 1A). Pearson correlation was
performed to analyze similarities between samples and revealed
that as a group, Barrett’s samples are more heterogeneous than are
the two reference groups (Figure 1B). Additionally, Barrett’s
esophagus is only slightly more similar to small intestine than it is
to normal esophagus in terms of the RNA expression profile. This
is surprising due to the striking shift in morphology of Barrett’s
esophagus toward a cell fate very reminiscent to that of the small
intestine. The means of the different pairwise comparisons are
summarized in Table S1. Same tissue comparisons have a 0.97
correlation coefficient while Barrett’s esophagus samples are
somewhat less homogenous with a correlation coefficient of 0.95.
Comparisons of Barrett’s esophagus with normal esophagus and
small intestine samples are 0.84 and 0.87, respectively. As a
reference value, the comparison of two normal tissues has a
correlation coefficient of 0.74. Next, gene lists were generated
comparing either Barrett’s esophagus or small intestine to normal
esophagus expression profiles. A Venn diagram demonstrates the
overlap in genes that are significantly altered (fold change=2; p
value,1610
25) (Figure 1C).
Several classic Barrett’s esophagus markers have been identified
previously. The performance of these markers was analyzed and
demonstrates that most of the markers are altered significantly in
our data sets (Figure 2A). Interestingly, two classic markers, Cdx2
and Intestinal Alkaline Phosphatase, were not detected in the
samples analyzed and suggest that molecular analysis of one
endoscopic biopsy sample per patient may not be sufficient to detect
all gene profile changes that may have occurred in each patient. To
further support this hypothesis of clonal gene expression we
analyzed surgical resection samples for Cdx1, Cdx2, Muc2,
Muc5AC and CK20 by immunohistochemistry (Figure 2B).
Regional expression was detected in these samples for all markers
and further supports the notion of clonal gene expression.
Alternatively, there may be post-transcriptional or translational
regulatory mechanisms that impact upon mosaic gene expression.
An analysis of keratin expression reveals significant changes
from those cytokeratins normally expressed in stratified squamous
epithelia to those expressed in columnar epithelium (Table 1).
Specifically, Keratin 13 is down-regulated 40 fold and Keratins 8
and 18 are upregulated 85 and 11 fold respectively. Additionally, a
variety of mucins are expressed in Barrett’s esophagus, notably
MUC5AC, which is normally expressed in the gastric epithelium
(Table 1).
Pathway analysis of the gene lists revealed alterations in the
expression of several genes involved in the myc pathway, including
several myc target genes (Table 2), although c-myc RNA
expression was not changed. Both CA2 and ODC1 are
upregulated 35 fold in Barrett’s epithelium. Of interest are the
expression changes of the myc inhibitors, MXD1 (MAD1) and
MXI1 (MAD2), which are down regulated 27 and 3.7 fold,
respectively. It is possible that c-Myc protein upregulation may be
due to MXI1 or MXD1 downregulation. This may lead to
enhanced c-myc protein expression. Indeed, c-myc protein has
been reported to be increased in Barrett’s esophagus [31,32].
Given that myc activity is involved in the differentiation
programs of several cell types, we hypothesized it may play a
role in the transdifferentiation process underlying Barrett’s
esophagus. Likewise, Cdx1 may be functionally related to the
development of Barrett’s esophagus. To test these hypotheses, we
transduced an immortalized esophageal keratinocyte cell line,
EPC2-hTERT [33], with c-myc alone or in combination with
Cdx1. Western blot analysis confirms overexpression of c-myc and
Cdx1 in EPC2-hTERT Myc-Cdx1 cells (Figure 3).
In order to model Barrett’s Esophagus, EPC2-hTERT Myc
cells alone or with Cdx1 were cultured in a 3-dimentional culture
system (organotypic culture) previously utilized in our lab to mimic
the microenvironment of the esophagus to study esophageal
tumorigenesis [34]. This system also recapitulates faithfully the
differentiation programs of the stratified epithelium of the
esophagus when using non-transformed EPC2-hTERT cells
[34]. Analysis of Myc, Myc-Cdx1 cells by histopathology reveals
no obvious changes in the stratification of the keratinocytes.
However, Alcian blue staining reveals a striking difference in
mucin production in these cells but not in parental EPC-hTERT
cells (Figure 4A and Figure S1). Specifically, only EPC-hTERT-
Myc-Cdx1 expressing cells have a subpopulation of cells that is
mucin-producing (Figure 4B). Immunohistochemistry staining of
Muc5AC (one of the mucins produced in Barrett’s esophagus)
reveals its expression in these cells (Figure 4C).
The basal cell layer of esophageal keratinocytes can be
identified with Keratins 14 or 19 (Figure 5 and data not shown).
Cdx1, c-Myc and Metaplasia
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culture can be identified with Keratin 13 staining (Figure 5).
Keratin expression analysis also demonstrates an altered gene
expression profile specifically in EPC-hTERT-Myc-Cdx1 express-
ing cells. Keratin 13 is downregulated while Keratin 8 is induced
(Figure 5). Keratin 19, expressed in simple columnar epithelium
and in the basal layer of stratified squamous esophageal
keratinocytes, was also evaluated. In addition to its disrupted
expression in basal cells, its expression is expanded into the
suprabasal region of Myc-Cdx1 expression cells.
Discussion
Taken together, these data suggest that c-myc and Cdx1
transcription factors may contribute to in the transdifferentiation
process leading to Barrett’s Esophagus. The combinatorial
expression of these genes leads to one of the two hallmark
morphologic features of Barrett’s esophagus, namely the production
of mucin in a subset of cells (goblet cells in Barrett’s esophagus). The
othermorphologicfeature not identified inthesecellsisthepresence
of columnar cells. This suggests two non-mutually exclusive
hypotheses. One is that other genetic alterations are required for
the shift in morphology. The second hypothesis is that the
upregulation of these genes precede the changes toward a columnar
morphology seen in Barrett’s esophagus and still require other
genetic alterations. Analysis of stratified squamous epithelium near
Barrett’s Esophagus provides some evidence for this. Cdx1, but not
Cdx2, expression is detected focally in this transitional region
(Figure S2). This, in combination with the fact that c-myc is already
expressed in esophageal keratinocytes, suggest that c-myc and Cdx1
may cooperate in some of the very earliest initiation stages towards
Barrett’s Esophagus.
Interestingly, some evidence exists for the cooperation of c-myc
with other transcription factors in epithelial transdifferentiation in
other tissues [35–38]. In the case of gastric intestinal metaplasia, c-
myc overexpression is observed similar to that for Barrett’s
Esophagus. C-myc expression analysis of atrophic gastritis samples
with mild and severe intestinal metaplasia reveal c-myc expression in
15% and 47% of samples respectively [38]. In the lung, a squamous
metaplastic process occurs before the development of squamous non-
Figure 1. Analysis of microarray data. A. PCA analysis of microarray data generated from 7 matched normal and Barrett’s Esophagus and 5 non-
related small intestine biopsies. Blue, green and red balls represent small intestine, normal esophagus and Barrett’s respectively. B. Pearson
correlation analysis of microarray data. C. Venn diagram representing the overlap of genes that are significantly different (Fold change=2; p
value=5610
25) in Barrett’s Esophagus and small intestine relative to normal esophagus.
doi:10.1371/journal.pone.0003534.g001
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metaplasia is observed with further augmentation as these lesions
progress toward squamous cancer [35].
If c-myc is indeed serving as a transcription factor that helps
other tissue-specific transcription factors to induce metaplasia, it
will be important to understand its role in these processes. This
may be achieved through direct or indirect interaction between c-
myc and Cdx1 with the induction of target genes. The notion of
myc serving as a potentiating transcription factor in a transdiffer-
entiation program is an attractive hypothesis. In addition to the
ability of c-myc to bind 10–15% of the promoters in the human
genome, it is likely to affect the transcription of even a larger
proportion of the genome by its ability to regulate methylation
patterns [39–42]. This notion of remodeling the genome and
altering the differentiation state and cell fate of adult tissues is
further supported by c-myc’s ability to cooperate in generating
induced pleuripotent stem (iPS) cells and an increased number of
tumor stem cells when myc is overexpressed [43–46].
We believe that c-myc and Cdx1 cooperate to induce the
initiation of a normal stratified squamous epithelium towards a
transdifferentiated state and that Barrett’s esophagus requires
additional genetic events for the development of a fully mature
transdifferentiation process (Figure 6). Several potential transcrip-
tion factors and signaling pathways are attractive candidates based
upon their functional roles in intestinal differentiation; two such
pathways are Notch and Hedgehog signaling. Their roles in
Barrett’s esophagus are under investigation.
Methods
Sample collection and Affymetrix analysis
Patients at the Hospital of the University of Pennsylvania
undergoing upper endoscopy were enrolled in the study under
IRB approval. Four biopsies were obtained each from both regions
of endoscopically appearing Barrett’s esophagus and normal
esophagus. Each set of biopsies was placed in RNA Later
(Ambion) for processing. Each biopsy was divided with a section
processed for RNA isolation and one for histology. RNA was
isolated by first homogenizing the tissue with a Brinkmann
homogenizer, passing it through a QIAshredder (Qiagen,) column
and isolating the RNA by RNeasy miniprep kit (Qiagen). Sample
collection and RNA extraction were performed as above for
normal small intestine biopsies. The formalin-fixed tissue samples
were processed, embedded, sectioned and stained with hemotox-
ylin and eosin, and evaluated in a blinded fashion for pathologic
diagnosis. Seven paired patient samples were selected for
Figure 2. Common Markers of Barrett’s Esophagus. A. Expression analysis of 8 common markers of Barrett’s Esophagus is represented
graphically. Green, yellow, and red bars represent Small intestine, normal esophagus and Barrett’s Esophagus respectively. B. Immunohistochemistry
of 5 common markers of Barrett’s Esophagus on serial sections of an esophageal adenocarcinoma surgical resection sample from a Barrett’s
Esophagus patient.
doi:10.1371/journal.pone.0003534.g002
Cdx1, c-Myc and Metaplasia
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intestinal metaplasia without gastric mucosa or dysplasia. cRNA
was prepped according to Affymetrix recommended protocols and
run on U133A version 1 chips. Since samples were not all prepped
simultaneously, they were grouped into 3 batches of experimental
samples for analysis in the 3-way mixed model ANOVA (see
below). Microarray data (accession # GSE13083) was deposited
with Gene Expression Omnibus at the NCBI (http://www.ncbi.
nlm.nih.gov/geo).
Bioinformatics analysis
These 19 Cel files were processed using Stratagene’s Array Lite
3.4 software using GC-RMA algorithm to calculate probeset
intensity values and to calculate Absent/Present/Marginal flags.
These intensity values were log2 transformed and then, GC-RMA
values were imported into Partek Genomics Suite 6.3 (beta)
retaining only those probesets flagged as present in at least 3 of 19
samples. A 3-way mixed model ANOVA was performed and
included a pairwise contrast that was patient matched between
normal esophagus and Barrett’s Esophagus. In a second analysis, a
1-way ANOVA was done and simultaneously performed a
pairwise contrast between normal small intestine and normal
esophagus. For each analysis p-values and fold change for probeset
were calculated. Principal component analysis (PCA) and Pearson
correlation analyses were executed using all probesets that passed
the 3 out of 19 present call filtering with no other limitations places
on each data set.
Cell Culture
Primary human esophageal keratinocytes, designated as EPC2,
were established as described previously[33]. Cells were main-
tained at 37uC and 5% CO2 using keratinocyte-SFM medium
(KSFM; Invitrogen) supplemented with 40 mg/mL bovine pitui-
tary extract (Invitrogen), 1.0 ng/mL EGF (Invitrogen), 100 U/mL
penicillin, and 100 mg/mL streptomycin (Invitrogen). Stable
transduction of primary esophageal cells with retroviral vectors
was described previously [33,47,48]. Vectors used were LXSN,
LMycSN, MIGR-Cdx1 and MIGR-Cdx2. Cells were passaged
48 h after infection and selected with 300 mg/mL G418 (Invitro-
Table 1. Keratin and Mucin Affymetrix Data
Squamous Expressed Genes
Fold change p-value
KRT1 2180 7.90E-05
KRT4 225 2.70E-02
KRT5 2123 6.00E-03
KRT6A 232 1.70E-02
KRT6B 284 8.00E-03
KRT10 22.7 4.40E-04
KRT13 240 2.00E-02
KRT14 217 3.30E-02
KRT15 267 2.00E-03
KRT16 234 1.00E-03
KRT17 26.4 1.60E-02
KRT23 24.3 3.60E-02
KRT24 222 3.00E-03
Columnar Expressed Genes
Fold change p-value
KRT7 4.6 4.67E-03
KRT8 85 3.31E-08
KRT18 10.9 5.59E-05
KRT19 3.4 1.05E-03
KRT20 369 6.09E-07
TFF1 294 4.50E-05
TFF2 203 1.81E-05
TFF3 508 1.11E-06
MUC2 106 4.58E-05
MUC5AC 289 7.49E-06
MUC13 164 4.96E-08
CD164 - sialomucin 6.8 1.71E-06
doi:10.1371/journal.pone.0003534.t001
Table 2. Affymetrix analysis of the Myc Pathway
Fold Change p-value
MXD1 (MAD1) 227 3.84E-07
MXI1 (MAD2) 23.7 4.82E-05
MYCN 3.1 2.97E-04
ODC1 36.3 2.06E-05
CA2 34.4 2.38E-05
doi:10.1371/journal.pone.0003534.t002
Figure 3. Western analysis of EPC2-hTERT esophageal kerati-
nocytes overexpressing c-myc alone or with Cdx1.
doi:10.1371/journal.pone.0003534.g003
Cdx1, c-Myc and Metaplasia
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sorted and GFP-positive cells were obtained.
Organotypic Culture
Organotypic culture was performed as previously described [34].
Briefly, a collagen/Matrigel matrix, containing 76.7% bovine tendon
acid-extracted collagen (Organogenesis), Matrigel Matrix (BD
Bioscience), 16 minimal essential medium with Earle’s salts
(BioWhittaker), 1.68 mM L-glutamine (Cellgro), 10% fetal bovine
serum (Hyclone), 0.15% sodium bicarbonate (BioWhittaker) was
mixed with 7.5610
4 human fetal esophageal fibroblasts. Following
7d a y s ,5 610
5 human esophageal keratinocytes were seeded on top
of the matrices. Cultures were fed with Epidermalization I medium
for 2 days, which is a 3:1 mixture DMEM (JRH Biosciences)/Ham’s
F-12 (Invitrogen) supplemented with 4 mM L-glutamine, 0.5 mg/mL
hydrocortisone, 0.1 mM O-phosphorylethanolamine, 20 pM triio-
dothyronine, 0.18 mM adenine, 1.88 mM CaCl2, 4 pM progester-
one (Sigma); 10 mg/mL insulin, 10 mg/mL transferrin, 5 mM
ethanolamine, 10 ng/mL selenium (ITES) (BioWhittaker), and
0.1% chelated newborn calf serum (Hyclone). For the next 2 days,
cultureswerefedwithEpidermalizationIImedium,whichisidentical
to Epidermalization I medium except that it contains 0.1%
unchelated newborn calf serum. Then, cultures were raised to an
air–liquid interface and cultured for 4 days in Epidermalization III
medium, which contains the same growth supplements as Epider-
malization I and II except that no progesterone is added and 2%
newborn calf serum is used. Cultures were then harvested by fixing in
neutral buffered formalin and later were paraffin-embedded.
Western Analysis
For Western blot analysis, cells were lysed in lysis buffer (10 mM
Tris?HCl at pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium
deoxycholate, 0.1% SDS, 1 mM EDTA, 2 mM sodium orthovana-
Figure 4. Analysis for mucin expression in EPC2-hTERT-Myc-
Cdx1 cells in organotypic culture. A. H&E analysis demonstrates
the stratified squamous morphology of keratinocytes in organotypic
cultures. B. Alcian blue staining for mucin demonstrates mucin
production only in EPC2-hTERT-Myc-Cdx1 cells. C. EPC2-hTERT-Myc-
Cdx1 cells are producing Muc5AC as demonstrated by immunohisto-
chemistry for Muc5AC.
doi:10.1371/journal.pone.0003534.g004
Figure 5. Keratin expression in EPC2-hTERT esophageal
keratinocytes overexpressing c-myc alone or with Cdx1.
Immunohistochemistry for Keratin 13, 8 and 19 was performed and
demonstrates that EPC2-hTERT-Myc-Cdx1 cells have altered keratin
expression.
doi:10.1371/journal.pone.0003534.g005
Figure 6. Model of the initial stages of the transdifferentiation
towards Barrett’s esophagus.
doi:10.1371/journal.pone.0003534.g006
Cdx1, c-Myc and Metaplasia
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Protein concentration was determined by the Bio-Rad protein assay.
Fifteen micrograms of protein were run on a 4%–12% SDS-PAGE
gel(Invitrogen)and transferred toaPVDFmembrane(Immobilon-P;
Millipore). Membranes were blocked in 5% nonfat milk (Bio-Rad) in
PBS with 0.05% Tween 20 (PBS-T) for 1 hr at room temperature,
then probed with primary antibody diluted in 5% milk in PBS-T
overnight at 4uC, washed with PBS-T, incubated with HRP-
conjugated secondary antibodies (GE Biotech; 1:5000 in PBS-T)
for 1 h at room temperature, and washed in PBS-T. The signal was
visualized using ECL Plus (Amersham Pharmacia Biotech) and
exposed to Blue Lite Autorad film (ISC-BioExpress). Primary
antibodies used were: Cdx1 (ab2400, Abcam), c-myc (NCL-cMYC,
Lab Visions), beta-actin (A5316, Sigma).
Immunohistochemistry
Immunohistochemistry was performed with the Vecta Elite kit
(Vector Laboratories) following the manufacturer’s protocol.
Briefly, paraffin sections were dewaxed with xylene and micro-
waved for 10 min in the presence of 10 mM citric acid buffer.
Endogenous peroxidases were quenched using hydrogen peroxide
before sections were blocked in avidin D-blocking reagent and
biotin-blocking reagent. Sections were incubated with primary
antibody overnight at 4uC and secondary antibody for 30 min at
37uC, and then signal was developed using the DAB substrate kit
for peroxidase (Vector Laboratories).Antibodies used were:
Cdx1(ab2400, Abcam), Cdx2 (MU392A-UC, Biogenex), Muc2
(VP-M656, Vector Labs), Muc5AC (VP-M657, Vector Labs),
Keratin 20 (M7019, DakoCytomation), c-myc (NCL-cMYC, Lab
Visions), Keratin 13 (NCL-CK13, Lab Visions), Keratin 19
(TROMA-III, Univ of Iowa Developmental Studies Hybridoma
Bank), Keratin 8 (RDI-PRO61038, Research Diagnostics).
Real-time PCR
RNA was isolated from cell lines using the RNeasy mini kit
(Qiagen) according to manufacturer’s instructions. cDNA synthesis
and amplification were performed using the WT-Ovation RNA
amplification System (NuGen Technologies) according to manufac-
turer’s instructions. Real-time PCR was performed and analyzed
using ABI PRISM 7000 sequence detection system software (PE
Applied Biosystems) using the Power SYBR Green PCR Master Mix
(PE Applied Biosystems) for Actin according to the manufacturer’s
instructions. Taqman assays were used with the Taqman Universal
PCR Master Mix (PE Applied Biosystems) according to manufac-
turer’s instructions. The following Taqman assays (PE Applied
Biosystems) used were: TFF1 (Hs00170216_m1), TFF2
(Hs00193719_m1), TFF3 (Hs00173625_m1), Muc2
(Hs00159374_m1), Muc5AC (Hs01365601_m1), Muc13
(Hs00217230_m1), CD164 (Hs00174789_m1), ODC1
(Hs00159739_m1), CA2 (Hs00163869_m1). Actin primers were:
Forward: CCT GGC ACC CAG GAC AAT, Reverse: GCC GAT
CCA CAC GGA GTA CT.
Supporting Information
Figure S1 Alcian blue staining of EPC2-hTERT cells. Mucin
staining of the parental cell line EPC2-hTERT is negative.
Found at: doi:10.1371/journal.pone.0003534.s001 (9.38 MB TIF)
Figure S2 Immunohistochemical analysis of stratified squamous
epithelium adjacent to Barrett’s esophagus. Cdx1, Cdx2 and c-
myc staining of the stratified squamous epithelium demonstrates
focal staining of Cdx1 which co-localizes with intense nuclear c-
myc staining. Cdx2 is not expressed in these regions. Circles
represent the same areas from serial sections.
Found at: doi:10.1371/journal.pone.0003534.s002 (9.82 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0003534.s003 (0.01 MB
DOC)
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